esmo 2017 hypersensitivity

2012;97:217-33. doi: 10.1159/000335637. In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Supportive. Median cycle and dose of carboplatin administered to women with or without hypersensitivity reactions. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 Int. 2017 Jun 20;18(6):1316. doi: 10.3390/ijms18061316. Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . Necessary cookies enable core functionality. reported that the majority (93%) of patients with a BRCA1/2 mutation develop carboplatin hypersensitivity, and that BRCA1/2 mutation is an independent risk factor for the development of carboplatin hypersensitivity. Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). Carboplatin-related hypersensitivity reactions were defined as symptoms and signs occurring minutes to hours after carboplatin administration. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for U.K. or U.S. based media ESMO 2017 abstract #Erbitux: 576P, 593P, 1068P, 1579. 2017;40(3):120-127. doi: 10.1159/000458443. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . doi: 10.1111/cas.12538, Kandel, M. J., Loehr, A., Harter, P., Traut, A., Gnauert, K., and du Bois, A. Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. The cumulative incidence of carboplatin-related hypersensitivity was 2% after 8 cycles, 6% after 14 cycles, 8% after 19 cycles, and 10% after 33 cycles, with a plateau beyond this cycle number (Figure 1A). By delivering the target, Symptoms and signs of hypersensitivity reactions amendable to desensitization. Cancer. B., Phillips, P. C., Kang, T. I., et al. Author Information. Prior investigations reported that a history of drug allergies correlates with the incidence of carboplatin-related hypersensitivity reactions (Libra et al., 2003; Sliesoraitis and Chikhale, 2005). J. Clin. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. Monitor. (Moon et al., 2013) BRCA1/2 mutation patients had early-onset carboplatin hypersensitivity at a lower cumulative exposure. Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). doi: 10.1016/j.ygyno.2016.09.027, Bruchim, I., Goldberg, A., Fishman, A., and Confino-Cohen, R. (2014). . However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. (2005). (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. (2009). Report of three cases. Request PDF | On Jul 13, 2017, Susana Rosell Kernen published Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines | Find, read and cite all the . official website and that any information you provide is encrypted Oncology 61, 129133. Blood. A history of drug or food allergy, the presence of malignant ascites, and the cumulative carboplatin dose are three independent predictive factors of carboplatin hypersensitivity in this survey. However, other studies have reported severe hypersensitivity reactions to cisplatin in patients with prior carboplatin hypersensitivity reactions (Zweizig et al., 1994; Dizon et al., 2002). (1999). This site uses cookies. It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Sixty-one of these patients were re-challenged with carboplatin following their initial hypersensitivity reaction. TABLE 3 Table 3. Compared to women without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly greater median cycle number (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test). J. Gynecol. Pediatric. The research protocol was reviewed and approved by the institutional review board of the hospital. The incidence of severe carboplatin-related hypersensitivity reactions ranges from 2 to 6%, with the lowest incidence occurring in our study. Front. (2003). Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. Open. official website and that any information you provide is encrypted Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Gender, age, ethnicity and race were similar between subgroups as were objective response rates (ORR) (64% CPI-treated v 62% CPI-nave). The total incidence of carboplatin-related hypersensitivity was 3.21% by the cycle of carboplatin. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. For more detailed information on the cookies we use, please check our Privacy Policy. Login to your ESMO accountto sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. A spotlight on alkaloid nanoformulations for the treatment of lung cancer. Integrating science into oncology for a better patient outcome, ESMO Designated Centres Community Session, Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the. The histological type was serous in 381 patients (51.8%) and clear cell in 148 patients (20.1%). Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. (2013). 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. (2006). This site uses cookies. Careers. Bookshelf However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). 19, 460465. Here's a summary of the new ESMO guidelines in 5 key areas: . (2009). 24, 2432. Most events occurred during chemotherapy. 144, 7782. Supporting your clinical decisions with ESMOs regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. (2005). Therefore, the preferred regimen for platinum-sensitive recurrent ovarian cancer is carboplatin combined with paclitaxel, liposomal doxorubicin, or gemcitabine. Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. (2012) demonstrated that carboplatin treatment can be continued successfully in patients whose hypersensitivity reactions are managed in a timely fashion. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. J. Clin. (2016). All accepted abstracts are available in theESMO 2017 Abstract Book. The https:// ensures that you are connecting to the HHS Vulnerability Disclosure, Help Table 2. Lacouture, V. Sibaud, P.A. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. 2023 Mar 15;210(6):709-720. doi: 10.4049/jimmunol.2100485. ESMO Clinical Practice Guidelines: Supportive and Palliative Care, ESMO Clinical Practice Guidelines on Palliative Care: Advanced Care Planning, Clinical Practice Guideline Anxiety and Depression, Anaemia and Iron Deficiency in Patients With Cancer, Clinical Practice Guidelines Management of Anaemia and Iron deficiency, Clinical Practice Guidelines Bone Health in Cancer Patients, Clinical Practice Guidelines Cancer Cachexia in Adult Patients, Clinical Practice Guidelines Management of cancer pain, Clinical Practice Guidelines - Cancer-related Fatigue, Clinical Practice Guidelines Care at the End of Life, Central Venous Access in Oncology: ESMO Clinical Practice Guidelines, Management of Chemotherapy Extravasation: ESMO Clinical Practice Guidelines, Clinical Practice Guidelines Constipation in advanced cancer, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. We also recorded the procedures applied to treat the hypersensitivity reactions and efforts to manage the side effects of carboplatin administration. 8600 Rockville Pike Pharmacol. Published in 2020 - Ann Oncol (2020) Authors: M.E. Cancer 19, 12841287. Necessary cookies enable core functionality. A total of 735 eligible women who underwent treatment for ovarian, fallopian tube, or primary peritoneal cancer were recruited this the study; 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. Patients with prior drug or food allergies should be closely monitored during carboplatin administration. J Oncol Pract. PMC Necessary cookies enable core functionality. Disclaimer. | DOI: 10.1097/HS9.0000000000000695. Cancer. Reactions to taxenes including paclitaxel and docetaxel present with pain as a neuromuscular symptoms in up to 4% of the patients. 2018 Oct 1;29(Suppl 4):iv260. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. Check the latest publications and updates here to make sure you dont miss anything. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. A. Oncol. Metrics. The imaging findings follow the American Thoracic Society and European Respiratory Society classification of interstitial pneumonia. eCollection 2017. doi: 10.1111/j.1525-1438.2007.01063.x, Genc, D. B., Canpolat, C., and Berrak, S. G. (2012). Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. The rate of hypersensitivity to carboplatin did not differ by patient age, menopausal status, disease entity, receipt of optimal debulking, or the amount of ascites. Borrs Cuartero J, Farzanegan Miano R, Torres Gorriz MC, Germn Snchez A, Aznar RC, Raducan I, Castell Carrascosa JV, Sanchez Hernandez A, Enrique E. Front Allergy. 2011 Aug;12(8):806-14. doi: 10.1016/S1470-2045(10)70208-4. 2017 Jul 1;28(suppl_4):iv119-iv142. Please enable it to take advantage of the complete set of features! A prospective single-center study. Patients should be observed closely for hypersensitivity reactions for a minimum of 30 minutes following each IV iron . (2010) described the use of cisplatin as an alternative to carboplatin. Utilizing Biologics in Drug Desensitization. Gynecol. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Risk factors for these reactions included advanced disease, serous histological type, malignant ascites, and history of drug allergies. Int. 31, 45254528. The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. There is a need to further characterise risk of anaphylaxis/hypersensitivity with PH IV/PH FDC SC to support safe administration outside of clinics. 84, 378382. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. doi: 10.3802/jgo.2013.24.4.342, Confino-Cohen, R., Fishman, A., Altaras, M., and Goldberg, A. Hypersensitivity & Infusion Reaction Management Author: Updated 2.21.19 Subject: SCC Pharmacy This site uses cookies. Symptoms and signs of hypersensitivity reactions amendable to desensitization. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. Anticancer. Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines. These scores have been defined by the guideline authors and validated by the ESMO Translational Research and Precision Medicine Working Group.17 g Selpercatinib is EMA approved for treating adults with advanced or metastatic RET fusion-positive TC who had already received lenvatinib or sorafenib. Met Based Drugs (2010) 2010 Available from: Markman M. Toxicities of the platinum antineoplastic agents. Immunotherapy 6, 905912. Summary format including algorithms, figures andtables for your presentations. (2005). Chan. Educate. Gynecol. Chemother. The https:// ensures that you are connecting to the Annals of Oncology (2021) 32 (suppl_5): S407-S446. All the statistical tests were two-tailed, and statistical significant level was defined as p-value < 0.05. J. Gynecol. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Table 6. Accessibility National Library of Medicine Previous data indicated that prior carboplatin exposure is the primary risk factor for carboplatin-related hypersensitivity reactions among all patients (Navo et al., 2006; Koshiba et al., 2009).

Vcu Academic Integrity Quiz, New York City Catholic Orphanage Records, Articles E